{"disease":{"id":"metastatic-castration-sensitive-prostate-cancer-mcspc","name":"metastatic castration sensitive prostate cancer mcspc"},"drugs":{"marketed":[{"drug_id":"darolutamide","indication_name":"Metastatic castration-sensitive prostate cancer (mCSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"darolutamide","indication_name":"Metastatic castration-sensitive prostate cancer (mCSPC) with docetaxel","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."}],"pipeline":[{"drug_id":"lutetium-177","indication_name":"Metastatic Castration Sensitive Prostate Cancer (mCSPC)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lutetium-177","generic_name":"lutetium-177","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"mCRPC","quality_score":null,"revenue":null,"mechanism":"mCRPC"}],"offLabel":[],"totalMarketed":2,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07086651","title":"A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)","phase":"","overall_status":"COMPLETED","enrollment_count":1300,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05701007","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","phase":"","overall_status":"COMPLETED","enrollment_count":1083,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07028853","title":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Pfizer","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}